Obleniobio
Lexington, US · 1 known investors
Oblenio Bio develops LBL-051, a tri-specific T-cell engager therapy targeting BCMA, CD19, and CD3 for treating refractory autoimmune diseases through B-cell and plasma cell depletion. The company aims to achieve long-term drug-free remission in autoimmune disease patients.
BiotechHealthtechMedical Devices